Zemba Mihail, Dumitrescu Otilia-Maria, Stamate Alina-Cristina, Barac Ileana Ramona, Tataru Calin Petru, Branisteanu Daniel Constantin
Department of Ophthalmology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Ophthalmology Department, "Dr. Carol Davila" Central Military Emergency University Hospital, 010825 Bucharest, Romania.
Diagnostics (Basel). 2022 May 5;12(5):1143. doi: 10.3390/diagnostics12051143.
The main objective of the article was to assess the surgical outcome of micropulse transscleral cyclophotocoagulation in patients presenting with glaucoma after penetrating keratoplasty. We conducted a retrospective study that included 26 eyes of 26 patients who presented with glaucoma after penetrating keratoplasty, and who were treated using micropulse transscleral cyclophotocoagulation between January 2017 and December 2020. The surgeries were performed using the Iridex Cyclo G6 MicroPulse P3 Probe. The intraocular pressure, mean number of antiglaucoma medications, visual acuity, corneal status, and postoperative complications were analyzed. The minimum follow-up period was 12 months. The success rate after 12 months was 76.9%. The baseline median intraocular pressure was 29 mm Hg and decreased to 18 mm Hg after 12 months. The median number of antiglaucoma medications was also reduced from three preoperatively to one after one year. In seven cases (29.92%), the visual acuity decreased and, in four cases (15.38%), the corneal graft was not transparent. We concluded that micropulse transscleral cyclophotocoagulation is an effective and safe method for the treatment of glaucoma after penetrating keratoplasty.
本文的主要目的是评估穿透性角膜移植术后青光眼患者行微脉冲经巩膜睫状体光凝术的手术效果。我们进行了一项回顾性研究,纳入了26例穿透性角膜移植术后出现青光眼的患者的26只眼,这些患者于2017年1月至2020年12月期间接受了微脉冲经巩膜睫状体光凝术治疗。手术使用Iridex Cyclo G6 MicroPulse P3探头进行。分析了眼压、抗青光眼药物的平均使用数量、视力、角膜状况和术后并发症。最短随访期为12个月。12个月后的成功率为76.9%。基线眼压中位数为29 mmHg,12个月后降至18 mmHg。抗青光眼药物的中位数也从术前的三种减少到一年后的一种。7例(29.92%)患者视力下降,4例(15.38%)角膜移植片不透明。我们得出结论,微脉冲经巩膜睫状体光凝术是治疗穿透性角膜移植术后青光眼的一种有效且安全的方法。